Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder

Table 1 Correlates of treatment engagement

	Outcome
Covariate Name	Duration of treatment HR^a (95% CI)	No. of Counselling Sessions OR^b (95% CI)	Average Dose Estimate^c (95% CI)
Duration of Regular Use, in years	0.54 (0.41, 0.71)	1.17 (0.97, 1.40)	0.65 (-1.34, 2.72)
Gender, binary, reference group = male (vs non-male^d)	0.90 (0.45, 1.69)	1.54 (1.01, 2.36)	0.44 (-4.15, 5.02)
Treatment group, binary; reference group = Placebo (vs Nabiximols)	0.60 (0.37, 0.96)	1.41 (1.02, 1.97)	-0.48 (-4.15, 3.22)
Average quantity of cannabis used, in grams per day	0.83 (0.70, 0.95)	1.11 (1.01, 1.21)	1.05 (0.16, 1.98)
Cannabis Problems Questionnaire, as z-score	0.99 (0.70, 1.42)	0.90 (0.72, 1.13)	-0.67 (-2.98, 1.80)
Self-coping and efficacy for quitting questionnaire, as z-score	0.96 (0.73, 1.26)	0.98 (0.83, 1.16)	-0.78 (-2.54, 1.06)
SF-36 Pain score, as z-score	1.21 (0.95, 1.56)	0.93 (0.78, 1.12)	-2.89 (-4.74, -0.99)
DASS total score, as z-score	1.10 (0.77, 1.55)	1.06 (0.83, 1.34)	-0.78 (-3.31, 1.74)
Insomnia Severity Index, as z-score	1.07 (0.83, 1.40)	0.96 (0.79, 1.17)	0.56 (-1.56, 2.67)

^az-score = (raw score – mean)/sd for variable in question. Hazard Ratio: difference in rate of dropout from study given 1-unit change in covariate (when noteworthy 95% CI excludes 1). Coefficients for each of the 11 time periods (weeks 1–11) are not included in this table (see eTable 3 Supplementary Materials)
^bOdds Ratio: difference in the odds or attending an extra counselling session, given a 1-unit change in the covariate (when noteworthy, 95% CI excludes 1)
^cchange in estimated mean sprays per day for 1-unit change in covariate (when noteworthy 95% CI excludes 0)
^dnon-male = female (n = 30) + non-binary (n = 1), collapsed together due to low numbers in non-binary group

ISSN: 1747-597X